344 results on '"Savidge, Tor"'
Search Results
302. Reply.
- Author
-
So SY, Savidge TC, and Shulman RJ
- Subjects
- Humans
- Published
- 2024
- Full Text
- View/download PDF
303. Impact of gut health and microbiome on autism spectrum disorder.
- Author
-
So SY and Savidge TC
- Abstract
Competing Interests: Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tp.amegroups.com/article/view/10.21037/tp-24-84/coif). The authors have no conflicts of interest to declare.
- Published
- 2024
- Full Text
- View/download PDF
304. Sex-Dependent Efficacy of Dietary Fiber in Pediatric Functional Abdominal Pain.
- Author
-
So SY, Badu S, Wu Q, Yalcinkaya N, Mirabile Y, Castaneda R, Musaad S, Heitkemper M, Savidge TC, and Shulman RJ
- Subjects
- Child, Female, Humans, Male, Abdominal Pain etiology, Abdominal Pain drug therapy, Cross-Sectional Studies, Dietary Fiber, Randomized Controlled Trials as Topic, Irritable Bowel Syndrome drug therapy, Psyllium
- Abstract
Background & Aims: Functional abdominal pain disorders (FAPDs) are more prevalent in female patients. Dietary fiber may alleviate FAPD symptoms; however, whether this effect is sex dependent remains unclear. We investigated the sex dependency of dietary fiber benefit on abdominal pain in children with FAPDs and explored the potential involvement of the gut microbiome., Methods: In 2 cross-sectional cohorts of children with FAPDs (n = 209) and healthy control individuals (n = 105), we correlated dietary fiber intake with abdominal pain symptoms after stratifying by sex. We also performed sex-stratified and sex-interaction analyses on data from a double-blind trial in children with irritable bowel syndrome randomized to psyllium fiber (n = 39) or placebo (n = 49) for 6 weeks. Shotgun metagenomics was used to investigate gut microbiome community changes potentially linking dietary fiber intake with abdominal pain., Results: In the cross-sectional cohorts, fiber intake inversely correlated with pain symptoms in boys (pain episodes: r = -0.24, P = .005; pain days: r = -0.24, P = 0.004) but not in girls. Similarly, in the randomized trial, psyllium fiber reduced the number of pain episodes in boys (P = .012) but not in girls. Generalized linear regression models confirmed that boys treated with psyllium fiber had greater reduction in pain episodes than girls (P = .007 for fiber × sex × time interaction). Age, sexual development, irritable bowel syndrome subtype, stool form, and microbiome composition were not significant determinants in the dietary fiber effects on pain reduction., Conclusions: Dietary fiber preferentially reduces abdominal pain frequency in boys, highlighting the importance of considering sex in future dietary intervention studies for FAPDs. (ClincialTrials.gov, Number NCT00526903)., (Copyright © 2024 AGA Institute. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
305. The pan-microbiome profiling system Taxa4Meta identifies clinical dysbiotic features and classifies diarrheal disease.
- Author
-
Wu Q, Badu S, So SY, Treangen TJ, and Savidge TC
- Subjects
- Humans, Dysbiosis, RNA, Ribosomal, 16S genetics, Diarrhea genetics, Gastrointestinal Microbiome, Microbiota
- Abstract
Targeted metagenomic sequencing is an emerging strategy to survey disease-specific microbiome biomarkers for clinical diagnosis and prognosis. However, this approach often yields inconsistent or conflicting results owing to inadequate study power and sequencing bias. We introduce Taxa4Meta, a bioinformatics pipeline explicitly designed to compensate for technical and demographic bias. We designed and validated Taxa4Meta for accurate taxonomic profiling of 16S rRNA amplicon data acquired from different sequencing strategies. Taxa4Meta offers significant potential in identifying clinical dysbiotic features that can reliably predict human disease, validated comprehensively via reanalysis of individual patient 16S data sets. We leveraged the power of Taxa4Meta's pan-microbiome profiling to generate 16S-based classifiers that exhibited excellent utility for stratification of diarrheal patients with Clostridioides difficile infection, irritable bowel syndrome, or inflammatory bowel diseases, which represent common misdiagnoses and pose significant challenges for clinical management. We believe that Taxa4Meta represents a new "best practices" approach to individual microbiome surveys that can be used to define gut dysbiosis at a population-scale level.
- Published
- 2024
- Full Text
- View/download PDF
306. Donor-recipient specificity and age-dependency in fecal microbiota therapy and probiotic resolution of gastrointestinal symptoms.
- Author
-
Wu Q, Boonma P, Badu S, Yalcinkaya N, So SY, Garey KW, Williams K, Arnold LE, Shulman RJ, Kellermayer R, and Savidge TC
- Subjects
- Adult, Humans, Child, Feces, Fecal Microbiota Transplantation, Autism Spectrum Disorder, Clostridioides difficile, Microbiota, Clostridium Infections therapy
- Abstract
Fecal microbiota transplantation (FMT) has proven to be an effective treatment for recurrent Clostridioides difficile infection (rCDI) in both adult and pediatric patients. However, as microbiome development is a critical factor in children, it remains unclear whether adult fecal donors can provide age-appropriate functional restoration in pediatric patients. To address this issue, we conducted an integrated systems approach and found that concordant donor strain engraftment, along with metabolite restoration, are associated with FMT outcomes in both adult and pediatric rCDI patients. Although functional restoration after FMT is not strain-specific, specialized metabolic functions are retained in pediatric patients when adult fecal donors are used. Furthermore, we demonstrated broad utility of high-resolution variant-calling by linking probiotic-strain engraftment with improved gastrointestinal symptoms in adults with irritable bowel syndrome and in children with autism spectrum disorder. Our findings emphasize the importance of strain-level identification when assessing the efficacy of probiotics and microbiota-based therapeutics., (© 2023. Springer Nature Limited.)
- Published
- 2023
- Full Text
- View/download PDF
307. Common Variable Immunodeficiency Patient Fecal Microbiota Transplant Recapitulates Gut Dysbiosis.
- Author
-
Hajjar J, Voigt A, Conner M, Swennes A, Fowler S, Calarge C, Mendonca D, Armstrong D, Chang CY, Walter J, Butte M, Savidge T, Oh J, Kheradmand F, and Petrosino J
- Abstract
Purpose: Patients with non-infectious complications have worse clinical outcomes in common variable immunodeficiency (CVID) than those with infections-only. Non-infectious complications are associated with gut microbiome aberrations, but there are no reductionist animal models that emulate CVID. Our aim in this study was to uncover potential microbiome roles in the development of non-infectious complications in CVID., Methods: We examined fecal whole genome shotgun sequencing from patients CVID, and non-infectious complications, infections-only, and their household controls. We also performed Fecal Microbiota transplant from CVID patients to Germ-Free Mice., Results: We found potentially pathogenic microbes Streptococcus parasanguinis and Erysipelatoclostridium ramosum were enriched in gut microbiomes of CVID patients with non-infectious complications. In contrast, Fusicatenibacter saccharivorans and Anaerostipes hadrus , known to suppress inflammation and promote healthy metabolism, were enriched in gut microbiomes of infections-only CVID patients. Fecal microbiota transplant from non-infectious complications, infections-only, and their household controls into germ-free mice revealed gut dysbiosis patterns in recipients from CVID patients with non-infectious complications, but not infections-only CVID, or household controls recipients., Conclusion: Our findings provide a proof of concept that fecal microbiota transplant from CVID patients with non-infectious complications to Germ-Free mice recapitulates microbiome alterations observed in the donors., Competing Interests: Competing Interests Joud Hajjar reports the following disclosures: received grants from Immune Deficiency Foundation, the US immunodeficiency network, Chao-physician Scientist award, the Texas Medical Center Digestive Diseases Center and the Jeffrey Modell Foundation. Received honorarium, consultation fees from Horizon, Pharming, Baxalta, CSL Behring, the National guard, and Al-Faisal University Hospital The other authors declare no conflicts of interest. All other authors declare no conflict of interest.
- Published
- 2023
- Full Text
- View/download PDF
308. Addressing barriers in FAIR data practices for biomedical data.
- Author
-
Hughes LD, Tsueng G, DiGiovanna J, Horvath TD, Rasmussen LV, Savidge TC, Stoeger T, Turkarslan S, Wu Q, Wu C, Su AI, and Pache L
- Published
- 2023
- Full Text
- View/download PDF
309. Developing a standardized but extendable framework to increase the findability of infectious disease datasets.
- Author
-
Tsueng G, Cano MAA, Bento J, Czech C, Kang M, Pache L, Rasmussen LV, Savidge TC, Starren J, Wu Q, Xin J, Yeaman MR, Zhou X, Su AI, Wu C, Brown L, Shabman RS, and Hughes LD
- Subjects
- Metadata, Reproducibility of Results, Humans, Communicable Diseases, Datasets as Topic standards
- Abstract
Biomedical datasets are increasing in size, stored in many repositories, and face challenges in FAIRness (findability, accessibility, interoperability, reusability). As a Consortium of infectious disease researchers from 15 Centers, we aim to adopt open science practices to promote transparency, encourage reproducibility, and accelerate research advances through data reuse. To improve FAIRness of our datasets and computational tools, we evaluated metadata standards across established biomedical data repositories. The vast majority do not adhere to a single standard, such as Schema.org, which is widely-adopted by generalist repositories. Consequently, datasets in these repositories are not findable in aggregation projects like Google Dataset Search. We alleviated this gap by creating a reusable metadata schema based on Schema.org and catalogued nearly 400 datasets and computational tools we collected. The approach is easily reusable to create schemas interoperable with community standards, but customized to a particular context. Our approach enabled data discovery, increased the reusability of datasets from a large research consortium, and accelerated research. Lastly, we discuss ongoing challenges with FAIRness beyond discoverability., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
310. Multisite Detection of Tn 1549 -Mediated vanB Vancomycin Resistance in Multidrug-Resistant Enterococcus faecalis ST6 in Texas and Florida.
- Author
-
Simar SR, Tran TT, Rydell KB, Panesso D, Contreras GA, Munita JM, Cifuentes RO, Abbo LM, Sahasrabhojane P, Dinh AQ, Axell-House DB, Savidge T, Shelburne SA, Hanson BM, and Arias CA
- Subjects
- Humans, Enterococcus faecalis genetics, Vancomycin Resistance genetics, Florida epidemiology, Texas epidemiology, Bacterial Proteins genetics, Anti-Bacterial Agents pharmacology, Enterococcus faecium, Vancomycin-Resistant Enterococci genetics, Gram-Positive Bacterial Infections drug therapy, Gram-Positive Bacterial Infections epidemiology
- Abstract
In the United States, vanB -mediated resistance in enterococci is rare. We characterized three sequence type (ST) 6, vancomycin-resistant Enterococcus faecalis isolates causing bacteremia in unique patients in spatiotemporally distinct settings. Isolates were recovered between 2018 and 2020 in two cities in the United States (Houston, TX; Miami, FL). The isolates harbored the vanB operon on a chromosomally located Tn 1549 transposon, and epidemiological data suggested multiple introductions of the vanB gene cluster into ST6 E. faecalis.
- Published
- 2023
- Full Text
- View/download PDF
311. Randomized placebo-controlled trial of oral tannin supplementation on COVID-19 symptoms, gut dysbiosis and cytokine response.
- Author
-
Molino S, Pisarevsky A, Badu S, Wu Q, Mingorance FL, Vega P, Stefanolo JP, Repetti J, Ludueña G, Pepa P, Olmos JI, Fermepin MR, Uehara T, Viciani E, Castagnetti A, Savidge T, and Piskorz MM
- Abstract
The clinical study aim was to investigate whether a tannin-based dietary supplementation could improve the efficacy of standard-of-care treatment of hospitalized COVID-19 patients by restoring gut microbiota function. Adverse events and immunomodulation post-tannin supplementation were also investigated. A total of 124 patients receiving standard-of-care treatment were randomized to oral tannin-based supplement or placebo for a total of 14 days. Longitudinal blood and stool samples were collected for cytokine and 16S rDNA microbiome profiling, and results were compared with 53 healthy controls. Although oral tannin supplementation did not result in clinical improvement or significant gut microbiome shifts after 14-days, a reduction in the inflammatory state was evident and significantly correlated with microbiota modulation. Among cytokines measured, MIP-1α was significantly decreased with tannin treatment (p = 0.03) where it correlated positively with IL-1β and TNF- α, and negatively with stool Bifidobacterium abundance., Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2022 The Authors. Published by Elsevier Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
312. Matrix metalloproteinase 7 contributes to intestinal barrier dysfunction by degrading tight junction protein Claudin-7.
- Author
-
Xiao Y, Lian H, Zhong XS, Krishnachaitanya SS, Cong Y, Dashwood RH, Savidge TC, Powell DW, Liu X, and Li Q
- Subjects
- Humans, Mice, Rats, Animals, Tight Junction Proteins metabolism, Dextran Sulfate toxicity, Matrix Metalloproteinase 7 genetics, Tumor Necrosis Factor-alpha metabolism, Interleukin-13 metabolism, Tight Junctions metabolism, Caco-2 Cells, Lipopolysaccharides adverse effects, Interleukin-4 metabolism, Inflammation metabolism, Mice, Knockout, Cytokines metabolism, Claudins genetics, Claudins metabolism, Trinitrobenzenes metabolism, Trinitrobenzenes therapeutic use, Sulfonic Acids adverse effects, Sulfonic Acids metabolism, Colitis pathology, Inflammatory Bowel Diseases metabolism, Colitis, Ulcerative pathology
- Abstract
Background: Previous studies implicated matrix metalloproteinases (MMPs), such as MMP-7, in inflammatory bowel diseases (IBD) by showing increased activity during inflammation of the gut. However, the pathophysiological roles of MMP-7 have not been clearly elucidated., Methods: The expression of MMP-7 was assessed in colonic biopsies of patients with ulcerative colitis (UC), in rodents with experimental colitis, and in cell-based assays with cytokines. Wild-type and MMP-7-null mice treated with dextran sulfate sodium (DSS) or trinitrobenzene sulfonic acid were used for determining the pro-inflammatory function(s) of MMP-7 in vivo ., Results: MMP-7 was highly expressed in patients with UC and in rodents with experimental colitis. IL-1β, IL-4, IL-13, TNFα, or lipopolysaccharide enhanced MMP-7 expression in human colonic epithelial cells, rat colonic smooth muscle cells, and THP-1-derived macrophages. Active MMP-7 degraded tight junction protein Claudin-7 in epithelial cells, cleaved recombinant Claudin-7 in cell-free system, and increased Caco-2 monolayer permeability. Immunostaining of colon biopsies revealed up-regulation of MMP-7 and reduction of Claudin-7 in UC patients. Compared to wild-type mice, Mmp7
-/- mice had significantly less inflammation in the colon upon DSS insult. DSS-induced alterations in junction proteins were mitigated in Mmp7-/- mice, suggesting that MMP-7 disrupts the intestinal barrier. MMP-7 antibody significantly ameliorated colonic inflammation and Claudin-7 reduction in 2 different rodent models of colitis., Summary: MMP-7 impairs intestinal epithelial barrier by cleavage of Claudin-7, and thus aggravating inflammation. These studies uncovered Claudin-7 as a novel substrate of MMP-7 in the intestinal epithelium and reinforced MMP-7 as a potential therapeutic target for IBD., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Xiao, Lian, Zhong, Krishnachaitanya, Cong, Dashwood, Savidge, Powell, Liu and Li.)- Published
- 2022
- Full Text
- View/download PDF
313. Emu: species-level microbial community profiling of full-length 16S rRNA Oxford Nanopore sequencing data.
- Author
-
Curry KD, Wang Q, Nute MG, Tyshaieva A, Reeves E, Soriano S, Wu Q, Graeber E, Finzer P, Mendling W, Savidge T, Villapol S, Dilthey A, and Treangen TJ
- Subjects
- Animals, Bacteria genetics, High-Throughput Nucleotide Sequencing methods, Phylogeny, RNA, Ribosomal, 16S genetics, Sequence Analysis, DNA methods, Dromaiidae genetics, Microbiota genetics, Nanopore Sequencing
- Abstract
16S ribosomal RNA-based analysis is the established standard for elucidating the composition of microbial communities. While short-read 16S rRNA analyses are largely confined to genus-level resolution at best, given that only a portion of the gene is sequenced, full-length 16S rRNA gene amplicon sequences have the potential to provide species-level accuracy. However, existing taxonomic identification algorithms are not optimized for the increased read length and error rate often observed in long-read data. Here we present Emu, an approach that uses an expectation-maximization algorithm to generate taxonomic abundance profiles from full-length 16S rRNA reads. Results produced from simulated datasets and mock communities show that Emu is capable of accurate microbial community profiling while obtaining fewer false positives and false negatives than alternative methods. Additionally, we illustrate a real-world application of Emu by comparing clinical sample composition estimates generated by an established whole-genome shotgun sequencing workflow with those returned by full-length 16S rRNA gene sequences processed with Emu., (© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.)
- Published
- 2022
- Full Text
- View/download PDF
314. Key difference between transition state stabilization and ground state destabilization: increasing atomic charge densities before or during enzyme-substrate binding.
- Author
-
Chen D, Li Y, Li X, Hong X, Fan X, and Savidge T
- Abstract
The origin of the enormous catalytic power of enzymes has been extensively studied through experimental and computational approaches. Although precise mechanisms are still subject to much debate, enzymes are thought to catalyze reactions by stabilizing transition states (TSs) or destabilizing ground states (GSs). By exploring the catalysis of various types of enzyme-substrate noncovalent interactions, we found that catalysis by TS stabilization and the catalysis by GS destabilization share common features by reducing the free energy barriers (Δ G
‡ s) of reactions, but are different in attaining the requirement for Δ G‡ reduction. Irrespective of whether enzymes catalyze reactions by TS stabilization or GS destabilization, they reduce Δ G‡ s by enhancing the charge densities of catalytic atoms that experience a reduction in charge density between GSs and TSs. Notably, in TS stabilization, the charge density of catalytic atoms is enhanced prior to enzyme-substrate binding; whereas in GS destabilization, the charge density of catalytic atoms is enhanced during the enzyme-substrate binding. Results show that TS stabilization and GS destabilization are not contradictory to each other and are consistent in reducing the Δ G‡ s of reactions. The full mechanism of enzyme catalysis includes the mechanism of reducing Δ G‡ and the mechanism of enhancing atomic charge densities. Our findings may help resolve the debate between TS stabilization and GS destabilization and assist our understanding of catalysis and the design of artificial enzymes., Competing Interests: The authors declare no competing financial interests., (This journal is © The Royal Society of Chemistry.)- Published
- 2022
- Full Text
- View/download PDF
315. KOMB: K-core based de novo characterization of copy number variation in microbiomes.
- Author
-
Balaji A, Sapoval N, Seto C, Leo Elworth RA, Fu Y, Nute MG, Savidge T, Segarra S, and Treangen TJ
- Abstract
Characterizing metagenomes via kmer-based, database-dependent taxonomic classification has yielded key insights into underlying microbiome dynamics. However, novel approaches are needed to track community dynamics and genomic flux within metagenomes, particularly in response to perturbations. We describe KOMB, a novel method for tracking genome level dynamics within microbiomes. KOMB utilizes K-core decomposition to identify Structural variations (SVs), specifically, population-level Copy Number Variation (CNV) within microbiomes. K-core decomposition partitions the graph into shells containing nodes of induced degree at least K, yielding reduced computational complexity compared to prior approaches. Through validation on a synthetic community, we show that KOMB recovers and profiles repetitive genomic regions in the sample. KOMB is shown to identify functionally-important regions in Human Microbiome Project datasets, and was used to analyze longitudinal data and identify keystone taxa in Fecal Microbiota Transplantation (FMT) samples. In summary, KOMB represents a novel graph-based, taxonomy-oblivious, and reference-free approach for tracking CNV within microbiomes. KOMB is open source and available for download at https://gitlab.com/treangenlab/komb., (© 2022 The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
316. Microbial metabolites: cause or consequence in gastrointestinal disease?
- Author
-
Fobofou SA and Savidge T
- Subjects
- Dysbiosis microbiology, Humans, COVID-19, Gastrointestinal Diseases, Gastrointestinal Microbiome, Microbiota
- Abstract
Systems biology studies have established that changes in gastrointestinal microbiome composition and function can adversely impact host physiology. Notable diseases synonymously associated with dysbiosis include inflammatory bowel diseases, cancer, metabolic disorders, and opportunistic and recurrent pathogen infections. However, there is a scarcity of mechanistic data that advances our understanding of taxonomic correlations with pathophysiological host-microbiome interactions. Generally, to survive a hostile gut environment, microbes are highly metabolically active and produce trans-kingdom signaling molecules to interact with competing microorganisms and the host. These specialized metabolites likely play important homeostatic roles, and identifying disease-specific taxa and their effector pathways can provide better strategies for diagnosis, treatment, and prevention, as well as the discovery of innovative therapeutics. The signaling role of microbial biotransformation products such as bile acids, short-chain fatty acids, polysaccharides, and dietary tryptophan is increasingly recognized, but little is known about the identity and function of metabolites that are synthesized by microbial biosynthetic gene clusters, including ribosomally synthesized and posttranslationally modified peptides (RiPPs), nonribosomal peptides (NRPs), polyketides (PKs), PK-NRP hybrids, and terpenes. Here we consider how bioactive natural products directly encoded by the human microbiome can contribute to the pathophysiology of gastrointestinal disease, cancer, autoimmune, antimicrobial-resistant bacterial and viral infections (including COVID-19). We also present strategies used to discover these compounds and the biological activities they exhibit, with consideration of therapeutic interventions that could emerge from understanding molecular causation in gut microbiome research.
- Published
- 2022
- Full Text
- View/download PDF
317. Mathematical models to study the biology of pathogens and the infectious diseases they cause.
- Author
-
Xavier JB, Monk JM, Poudel S, Norsigian CJ, Sastry AV, Liao C, Bento J, Suchard MA, Arrieta-Ortiz ML, Peterson EJR, Baliga NS, Stoeger T, Ruffin F, Richardson RAK, Gao CA, Horvath TD, Haag AM, Wu Q, Savidge T, and Yeaman MR
- Abstract
Mathematical models have many applications in infectious diseases: epidemiologists use them to forecast outbreaks and design containment strategies; systems biologists use them to study complex processes sustaining pathogens, from the metabolic networks empowering microbial cells to ecological networks in the microbiome that protects its host. Here, we (1) review important models relevant to infectious diseases, (2) draw parallels among models ranging widely in scale. We end by discussing a minimal set of information for a model to promote its use by others and to enable predictions that help us better fight pathogens and the diseases they cause., (© 2022 The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
318. Fecal Microbiota Transplantation Commonly Failed in Children With Co-Morbidities.
- Author
-
Kellermayer R, Wu Q, Nagy-Szakal D, Queliza K, Ihekweazu FD, Bocchini CE, Magee AR, Oezguen N, Spinler JK, Hollister EB, Shulman RJ, Versalovic J, Luna RA, and Savidge TC
- Subjects
- Child, Fecal Microbiota Transplantation, Feces, Humans, Morbidity, Prospective Studies, RNA, Ribosomal, 16S genetics, Recurrence, Treatment Outcome, Clostridioides difficile, Clostridium Infections therapy
- Abstract
Objectives: Fecal microbiota transplantation (FMT) is arguably the most effective treatment for recurrent Clostridioides difficile infection (rCDI). Clinical reports on pediatric FMT have not systematically evaluated microbiome restoration in patients with co-morbidities. Here, we determined whether FMT recipient age and underlying co-morbidity influenced clinical outcomes and microbiome restoration when treated from shared fecal donor sources., Methods: Eighteen rCDI patients participating in a single-center, open-label prospective cohort study received fecal preparation from a self-designated (single case) or two universal donors. Twelve age-matched healthy children and four pediatric ulcerative colitis (UC) cases from an independent serial FMT trial, but with a shared fecal donor were examined as controls for microbiome restoration using 16S rRNA gene sequencing of longitudinal fecal specimens., Results: FMT was significantly more effective in rCDI recipients without underlying chronic co-morbidities where fecal microbiome composition in post-transplant responders was restored to levels of healthy children. Microbiome reconstitution was not associated with symptomatic resolution in some rCDI patients who had co-morbidities. Significant elevation in Bacteroidaceae, Bifidobacteriaceae, Lachnospiraceae, Ruminococcaceae, and Erysipelotrichaceae was consistently observed in pediatric rCDI responders, while Enterobacteriaceae decreased, correlating with augmented complex carbohydrate degradation capacity., Conclusion: Recipient background disease was a significant risk factor influencing FMT outcomes. Special attention should be taken when considering FMT for pediatric rCDI patients with underlying co-morbidities., Competing Interests: Conflicts of Interest: These authors disclose the following: T.C.S. received research funding from Merck, Nivalis, Cubist, Mead Johnson, Rebiotix, BioFire, Assembly BioSciences, and has served on the advisory board for Rebiotix and BioFire. R.J.S. provided consultancy for Nutrinia, IMHealth, and Biogaia AB, and received restricted research support from Mead-Johnson; J.V. received unrestricted research support from Biogaia AB (Stockholm, Sweden) and serves on the Scientific Advisory Boards of Biomica, Plexus Worldwide, and Seed Health; no study sponsors were involved in the design of the study, collection, analysis, or interpretation of the data, or the writing of the manuscript. The remaining authors disclose no conflicts., (Copyright © 2021 by European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.)
- Published
- 2022
- Full Text
- View/download PDF
319. Gut feelings: the microbiota-gut-brain axis on steroids.
- Author
-
So SY and Savidge TC
- Subjects
- Animals, Brain physiology, Enteric Nervous System physiology, Humans, Brain-Gut Axis physiology, Emotions physiology, Gastrointestinal Microbiome physiology, Steroids metabolism
- Abstract
The intricate connection between central and enteric nervous systems is well established with emerging evidence linking gut microbiota function as a significant new contributor to gut-brain axis signaling. Several microbial signals contribute to altered gut-brain communications, with steroids representing an important biological class that impacts central and enteric nervous system function. Neuroactive steroids contribute pathologically to neurological disorders, including dementia and depression, by modulating the activity of neuroreceptors. However, limited information is available on the influence of neuroactive steroids on the enteric nervous system and gastrointestinal function. In this review, we outline how steroids can modulate enteric nervous system function by focusing on their influence on different receptors that are present in the intestine in health and disease. We also highlight the potential role of the gut microbiota in modulating neuroactive steroid signaling along the gut-brain axis.
- Published
- 2022
- Full Text
- View/download PDF
320. Yeast β-glucan reduces obesity-associated Bilophila abundance and modulates bile acid metabolism in healthy and high-fat diet mouse models.
- Author
-
So SY, Wu Q, Leung KS, Kundi ZM, Savidge TC, and El-Nezami H
- Subjects
- Animals, Bilophila genetics, Cholesterol 7-alpha-Hydroxylase genetics, Cholesterol 7-alpha-Hydroxylase metabolism, Diet, High-Fat, Disease Models, Animal, Glucagon-Like Peptide-1 Receptor genetics, Glucagon-Like Peptide-1 Receptor metabolism, Insulin Resistance, Intestine, Small metabolism, Inulin administration & dosage, Male, Mice, Inbred C57BL, Obesity metabolism, Obesity microbiology, Receptors, Cytoplasmic and Nuclear genetics, Receptors, Cytoplasmic and Nuclear metabolism, Signal Transduction, beta-Glucans isolation & purification, Mice, Bile Acids and Salts metabolism, Bilophila growth & development, Dietary Fiber administration & dosage, Gastrointestinal Microbiome, Intestine, Small microbiology, Liver metabolism, Obesity diet therapy, Yeasts metabolism, beta-Glucans administration & dosage
- Abstract
Emerging evidence links dietary fiber with altered gut microbiota composition and bile acid signaling in maintaining metabolic health. Yeast β-glucan (Y-BG) is a dietary supplement known for its immunomodulatory effect, yet its impact on the gut microbiota and bile acid composition remains unclear. This study investigated whether dietary forms of Y-BG modulate these gut-derived signals. We performed 4-wk dietary supplementation in healthy mice to evaluate the effects of different fiber composition (soluble vs. particulate Y-BG) and dose (0.1% vs. 2%). We found that 2% particulate Y-BG induced robust gut microbiota community shifts with elevated liver Cyp7a1 mRNA abundance and bile acid synthesis. These diet-induced responses were notably different when compared with the prebiotic inulin, and included a marked reduction in fecal Bilophila abundance which we demonstrated as translatable to obesity in population-scale American Gut and TwinsUK clinical cohorts. This prompted us to test whether 2% Y-BG maintained metabolic health in mice fed 60% HFD over 13 wk. Y-BG consistently altered the gut microbiota composition and reduced Bilophila abundance, with trends observed in improvement of metabolic phenotype. Notably, Y-BG improved insulin sensitization and this was associated with enhanced ileal Glpr1r mRNA accumulation and reduced Bilophila abundance. Collectively, our results demonstrate that Y-BG modulates gut microbiota community composition and bile acid signaling, but the dietary regime needs to be optimized to facilitate clinical improvement in metabolic phenotype in an aggressive high-fat diet animal model. NEW & NOTEWORTHY The study shows that dietary Y-BG supplementation modulated gut microbiota, bile acid metabolism and associated signaling pathways. Y-BG significantly reduced Bilophila abundance which is associated with obesity in human cohorts. Correlation analysis confirmed functional interactions between bile acid composition, gut microbiota, and metabolic phenotype, although clinical benefit did not reach significance in an aggressive obesity model. Gut microbiota and bile acids correlated with metabolic parameters, indicating future potential of dietary Y-BG modulation of metabolic pathways.
- Published
- 2021
- Full Text
- View/download PDF
321. Probiotic VSL#3 Treatment Reduces Colonic Permeability and Abdominal Pain Symptoms in Patients With Irritable Bowel Syndrome.
- Author
-
Boonma P, Shapiro JM, Hollister EB, Badu S, Wu Q, Weidler EM, Abraham BP, Devaraj S, Luna RA, Versalovic J, Heitkemper MM, Savidge TC, and Shulman RJ
- Abstract
Background: Little is known regarding the clinical impact of treatment and treatment duration of probiotic VSL#3 on gut and microbiome function in irritable bowel syndrome (IBS). As part of a safety trial, we assessed the effect of VSL#3 treatment duration on abdominal pain, stooling, gut permeability, microbiome composition and function. Methods: Adults with IBS were randomized into an open label trial to receive the probiotic VSL#3 for 4 or 8 weeks. Adverse events, abdominal pain, and stooling patterns were recorded daily. Gut permeability, fecal bile acid levels, and microbiome composition were profiled at baseline and after treatment. Results: Fifteen subjects completed the trial (4-week: n = 8; 8-week: n = 7). Number of pain episodes decreased in both groups ( P = 0.049 and P = 0.034; 4- vs. 8-week, respectively). Probiotic organisms contained in VSL#3 were detected in feces by whole shotgun metagenomic sequencing analysis and relative abundances of Streptococcus thermophilus, Bifidobacterium animalis, Lactobacillus plantarum , and Lactobacillus casei subsp. paraccasei correlated significantly with improved abdominal pain symptoms and colonic permeability at study completion. Although abdominal pain correlated significantly with the detection of probiotic species at study completion, a composite view of gut microbiome structure showed no changes in community diversity or composition after VSL#3 treatment. Conclusions: Probiotic organisms identified in stool correlated significantly with improvement in colonic permeability and clinical symptoms, prompting future studies to investigate the mechanistic role of VSL#3 and colonic permeability in IBS pathophysiology in a larger randomized controlled trial. Clinical Trial Registration: www.clinicaltrials.gov, Identifier: NCT00971711., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Boonma, Shapiro, Hollister, Badu, Wu, Weidler, Abraham, Devaraj, Luna, Versalovic, Heitkemper, Savidge and Shulman.)
- Published
- 2021
- Full Text
- View/download PDF
322. A multisite genomic epidemiology study of Clostridioides difficile infections in the USA supports differential roles of healthcare versus community spread for two common strains.
- Author
-
Miles-Jay A, Young VB, Pamer EG, Savidge TC, Kamboj M, Garey KW, and Snitkin ES
- Subjects
- Bayes Theorem, Clostridioides difficile classification, Cross Infection epidemiology, Diarrhea microbiology, Feces microbiology, Genome, Bacterial, Hospitals, Humans, Phylogeny, Ribotyping, United States epidemiology, Whole Genome Sequencing, Clostridioides difficile genetics, Clostridium Infections epidemiology, Clostridium Infections transmission, Delivery of Health Care, Genomics, Molecular Epidemiology
- Abstract
Clostridioides difficile is the leading cause of healthcare-associated infectious diarrhoea. However, it is increasingly appreciated that healthcare-associated infections derive from both community and healthcare environments, and that the primary sites of C. difficile transmission may be strain-dependent. We conducted a multisite genomic epidemiology study to assess differential genomic evidence of healthcare vs community spread for two of the most common C. difficile strains in the USA: sequence type (ST) 1 (associated with ribotype 027) and ST2 (associated with ribotype 014/020). We performed whole-genome sequencing and phylogenetic analyses on 382 ST1 and ST2 C. difficile isolates recovered from stool specimens collected during standard clinical care at 3 geographically distinct US medical centres between 2010 and 2017. ST1 and ST2 isolates both displayed some evidence of phylogenetic clustering by study site, but clustering was stronger and more apparent in ST1, consistent with our healthcare-based study more comprehensively sampling local transmission of ST1 compared to ST2 strains. Analyses of pairwise single-nucleotide variant (SNV) distance distributions were also consistent with more evidence of healthcare transmission of ST1 compared to ST2, with 44 % of ST1 isolates being within two SNVs of another isolate from the same geographical collection site compared to 5.5 % of ST2 isolates ( P -value=<0.001). Conversely, ST2 isolates were more likely to have close genetic neighbours across disparate geographical sites compared to ST1 isolates, further supporting non-healthcare routes of spread for ST2 and highlighting the potential for misattributing genomic similarity among ST2 isolates to recent healthcare transmission. Finally, we estimated a lower evolutionary rate for the ST2 lineage compared to the ST1 lineage using Bayesian timed phylogenomic analyses, and hypothesize that this may contribute to observed differences in geographical concordance among closely related isolates. Together, these findings suggest that ST1 and ST2, while both common causes of C. difficile infection in hospitals, show differential reliance on community and hospital spread. This conclusion supports the need for strain-specific criteria for interpreting genomic linkages and emphasizes the importance of considering differences in the epidemiology of circulating strains when devising interventions to reduce the burden of C. difficile infections.
- Published
- 2021
- Full Text
- View/download PDF
323. Sex-Bias in Irritable Bowel Syndrome: Linking Steroids to the Gut-Brain Axis.
- Author
-
So SY and Savidge TC
- Subjects
- Animals, Epigenesis, Genetic, Female, Gastrointestinal Microbiome, Humans, Irritable Bowel Syndrome microbiology, Irritable Bowel Syndrome therapy, Male, Brain-Gut Axis, Irritable Bowel Syndrome metabolism, Sex Characteristics, Steroids metabolism
- Abstract
Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder that is more common in females. Despite its high global incidence, the disease mechanism is still unclear and therapeutic options remain limited. The sexual dimorphism in IBS incidence suggests that sex steroids play a role in disease onset and symptoms severity. This review considers sex steroids and their involvement in IBS symptoms and the underlying disease mechanisms. Estrogens and androgens play important regulatory roles in IBS symptomology, including visceral sensitivity, gut motility and psychological conditions, possibly through modulating the gut-brain axis. Steroids are regulators of hypothalamic-pituitary-adrenal activity and autonomic nervous system function. They also modulate gut microbiota and enteric nervous systems, impacting serotonin and mast cell signaling. Sex steroids also facilitate bidirectional cross-talk between the microbiota and host following bacterial transformation and recycling of steroids by the intestine. The sex-specific interplay between sex steroids and the host provides neuroendocrinology insight into the pathophysiology, epigenetics and treatment of IBS patients., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 So and Savidge.)
- Published
- 2021
- Full Text
- View/download PDF
324. Predicting Inflammatory Bowel Disease Symptoms Onset: Nitrous Take on Gut Bacteria Is No Laughing Matter.
- Author
-
Savidge T
- Subjects
- Bacteria, Humans, Nitrogen, Colitis, Inflammatory Bowel Diseases
- Published
- 2021
- Full Text
- View/download PDF
325. Systems approaches for the clinical diagnosis of Clostridioides difficile infection.
- Author
-
Wu Q and Savidge TC
- Subjects
- Clostridium Infections immunology, Clostridium Infections microbiology, Gastrointestinal Microbiome, Humans, Clostridium Infections diagnosis, Systems Biology methods
- Abstract
Clostridioides difficile infection (CDI) is an urgent threat to global public health. Patient susceptibility to C. difficile is highly dependent on host immune status and gut dysbiosis resulting in loss of protective microbiota consortia that prevent spore germination, pathogen colonization, and disease pathogenesis. Recent clinical studies highlight the problems of differentiating symptomatic CDI from asymptomatic C. difficile carriage in patients with diarrhea. In this review, we consider how integration of microbiome and host immune systems biology data may aid in the clinical diagnosis of CDI when validated against gold standard testing and combined with standard microbiology laboratory assays., (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
326. Microbiota stratification identifies disease-specific alterations in neuro-Behçet's disease and multiple sclerosis.
- Author
-
Oezguen N, Yalcinkaya N, Kücükali CI, Dahdouli M, Hollister EB, Luna RA, Türkoglu R, Kürtüncü M, Eraksoy M, Savidge TC, and Tüzün E
- Subjects
- Adult, Humans, RNA, Ribosomal, 16S, Behcet Syndrome microbiology, Dysbiosis microbiology, Gastrointestinal Microbiome, Microbiota, Multiple Sclerosis microbiology
- Abstract
Objectives: Altered gut microbiota community dynamics are implicated in diverse human diseases including inflammatory disorders such as neuro-Behçet's disease (NBD) and multiple sclerosis (MS). Traditionally, microbiota communities are analysed uniformly across control and disease groups, but recent reports of subsample clustering indicate a potential need for analytical stratification. The objectives of this study are to analyse and compare faecal microbiota community signatures of ethno-geographical, age and gender matched adult healthy controls (HC), MS and NBD individuals., Methods: Faecal microbiota community compositions in adult HC (n=14), NBD patients (n=13) and MS (n=13) were analysed by 16S rRNA gene sequencing and standard bioinformatics pipelines. Bipartite networks were then used to identify and re-analyse dominant compositional clusters in respective groups., Results: We identified Prevotella and Bacteroides dominated subsample clusters in HC, MS, and NBD cohorts. Our study confirmed previous reports that Prevotella is a major dysbiotic target in these diseases. We demonstrate that subsample stratification is required to identify significant disease-associated microbiota community shifts with increased Clostridiales evident in Prevotella-stratified NBD and Bacteroides-stratified MS patients., Conclusions: Patient cohort stratification may be needed to facilitate identification of common microbiota community shifts for causation testing in disease.
- Published
- 2019
327. Complete Genome Sequence of Clostridioides difficile Ribotype 255 Strain Mta-79, Assembled Using Oxford Nanopore and Illumina Sequencing.
- Author
-
Spinler JK, Gonzales-Luna AJ, Raza S, Runge JK, Luna RA, Savidge TC, and Garey KW
- Abstract
Hybrid de novo assembly of Illumina/Nanopore sequence data produced a complete circular sequence of the chromosome for a Clostridioides difficile ribotype 255 (RT255) isolate from an elderly patient with recurrent C. difficile infection (CDI). This provides a high-quality representative sequence for the RT255 lineage., (Copyright © 2019 Spinler et al.)
- Published
- 2019
- Full Text
- View/download PDF
328. Gastrointestinal dysfunction in patients and mice expressing the autism-associated R451C mutation in neuroligin-3.
- Author
-
Hosie S, Ellis M, Swaminathan M, Ramalhosa F, Seger GO, Balasuriya GK, Gillberg C, Råstam M, Churilov L, McKeown SJ, Yalcinkaya N, Urvil P, Savidge T, Bell CA, Bodin O, Wood J, Franks AE, Bornstein JC, and Hill-Yardin EL
- Subjects
- Animals, Comorbidity, Gastrointestinal Diseases physiopathology, Gastrointestinal Microbiome genetics, Gastrointestinal Transit genetics, Humans, Male, Mice, Myenteric Plexus physiopathology, Neurons physiology, Phenotype, Autistic Disorder genetics, Cell Adhesion Molecules, Neuronal genetics, DNA Mutational Analysis, Gastrointestinal Diseases genetics, Gene Expression genetics, Membrane Proteins genetics, Nerve Tissue Proteins genetics
- Abstract
Gastrointestinal (GI) problems constitute an important comorbidity in many patients with autism. Multiple mutations in the neuroligin family of synaptic adhesion molecules are implicated in autism, however whether they are expressed and impact GI function via changes in the enteric nervous system is unknown. We report the GI symptoms of two brothers with autism and an R451C mutation in Nlgn3 encoding the synaptic adhesion protein, neuroligin-3. We confirm the presence of an array of synaptic genes in the murine GI tract and investigate the impact of impaired synaptic protein expression in mice carrying the human neuroligin-3 R451C missense mutation (NL3
R451C ). Assessing in vivo gut dysfunction, we report faster small intestinal transit in NL3R451C compared to wild-type mice. Using an ex vivo colonic motility assay, we show increased sensitivity to GABAA receptor modulation in NL3R451C mice, a well-established Central Nervous System (CNS) feature associated with this mutation. We further show increased numbers of small intestine myenteric neurons in NL3R451C mice. Although we observed altered sensitivity to GABAA receptor modulators in the colon, there was no change in colonic neuronal numbers including the number of GABA-immunoreactive myenteric neurons. We further identified altered fecal microbial communities in NL3R451C mice. These results suggest that the R451C mutation affects small intestinal and colonic function and alter neuronal numbers in the small intestine as well as impact fecal microbes. Our findings identify a novel GI phenotype associated with the R451C mutation and highlight NL3R451C mice as a useful preclinical model of GI dysfunction in autism. Autism Res 2019, 12: 1043-1056. © 2019 International Society for Autism Research, Wiley Periodicals, Inc. LAY SUMMARY: People with autism commonly experience gastrointestinal problems, however the cause is unknown. We report gut symptoms in patients with the autism-associated R451C mutation encoding the neuroligin-3 protein. We show that many of the genes implicated in autism are expressed in mouse gut. The neuroligin-3 R451C mutation alters the enteric nervous system, causes gastrointestinal dysfunction, and disrupts gut microbe populations in mice. Gut dysfunction in autism could be due to mutations that affect neuronal communication., (© 2019 The Authors. Autism Research published by International Society for Autism Research published by Wiley Periodicals, Inc.)- Published
- 2019
- Full Text
- View/download PDF
329. Role of Bile in Infectious Disease: the Gall of 7α-Dehydroxylating Gut Bacteria.
- Author
-
Savidge T and Sorg JA
- Subjects
- Anti-Bacterial Agents, Bile, Bile Acids and Salts, Clostridioides difficile, Microbiota
- Abstract
Local antibiotics and quorum sensors produced by gut bacteria regulate microbiota community structure and guard against pathogens. In this issue of Cell Chemical Biology, Kang et al. (2019) guide us through a reciprocal host-antimicrobial interplay that redefines our understanding of Clostridioides (Clostridium) difficile pathogenesis., (Published by Elsevier Ltd.)
- Published
- 2019
- Full Text
- View/download PDF
330. Neonatal Antibiotics Disrupt Motility and Enteric Neural Circuits in Mouse Colon.
- Author
-
Hung LY, Boonma P, Unterweger P, Parathan P, Haag A, Luna RA, Bornstein JC, Savidge TC, and Foong JPP
- Subjects
- Animals, Animals, Newborn, Colon microbiology, Colon physiology, Mice, Anti-Bacterial Agents adverse effects, Colon drug effects, Enteric Nervous System drug effects, Gastrointestinal Microbiome drug effects, Gastrointestinal Motility drug effects
- Published
- 2019
- Full Text
- View/download PDF
331. The shielding effect of metal complexes on the binding affinities of ligands to metalloproteins.
- Author
-
Chen D, Li Y, Guo W, Li Y, Savidge T, Li X, and Fan X
- Subjects
- Models, Chemical, Protein Binding drug effects, Metalloproteins metabolism, Metals chemistry, Metals pharmacology
- Abstract
Metal ions are important regulatory cofactors in a wide variety of proteins. Conventional wisdom suggests that stronger metal-ligand interactions have a larger effect on the ligand binding affinity. However, some experimental data do not support this conventional wisdom. In this study, we used a theoretical derivation approach to explore the effect of metal-ligand interactions on ligand binding affinities. Both theoretical derivation and experimental data indicate that metal-ligand interactions weaken the original interactions of the metal ions, which reduce the contributions of the metal-ligand interactions to the ligand binding affinities. The shielding effect is so large that some strong metal-ligand interactions contribute little to the ligand binding affinities. The binding free energies contributed by metal-ligand interactions have a limited relationship with the strengths of the interactions. Considering that the shielding effect of metal complexes is essential for accurately modelling metal-ligand interactions, our findings challenge the conventional wisdom and represent a significant advance for the design of drugs targeted for metalloproteins and for exploring the enormous catalytic power of metalloproteins.
- Published
- 2018
- Full Text
- View/download PDF
332. Neonatal Colonic Inflammation Epigenetically Aggravates Epithelial Inflammatory Responses to Injury in Adult Life.
- Author
-
Zhong XS, Winston JH, Luo X, Kline KT, Nayeem SZ, Cong Y, Savidge TC, Dashwood RH, Powell DW, and Li Q
- Abstract
Background & Aims: Early life adversity is considered a risk factor for the development of gastrointestinal diseases, including inflammatory bowel disease. We hypothesized that early life colonic inflammation causes susceptibility to aggravated overexpression of interleukin (IL)1β., Methods: We developed a 2-hit rat model in which neonatal inflammation (NI) and adult inflammation (AI) were induced by trinitrobenzene sulfonic acid., Results: Aggravated immune responses were observed in NI + AI rats, including a sustained up-regulation of IL1β and other cytokines. In parallel with exacerbated loss of inhibitor of kappa B alpha expression, NI + AI rats showed hyperacetylation of histone H4K12 and increased V-Rel Avian Reticuloendotheliosis Viral Oncogene Homolog A binding on the IL1B promoter, accompanied by high levels of norepinephrine/epinephrine. Propranolol, a β-blocker, markedly ameliorated the inflammatory response and IL1β overexpression by mitigating against epigenetic modifications. Adrenalectomy abrogated NI-induced disease susceptibility whereas yohimbine sensitized the epithelium for exacerbated immune response. The macrophages of NI rats produced more IL1β than controls after exposure to lipopolysaccharide (LPS), suggesting hypersensitization; incubation with LPS plus Foradil (Sigma, St. Louis, MO), a β2-agonist, induced a greater IL1β expression than LPS alone. Epinephrine and Foradil also exacerbated LPS-induced IL1β activation in human THP-1-derived macrophages, by increasing acetylated H4K12, and these increases were abrogated by propranolol., Conclusions: NI sensitizes the colon epithelium for exacerbated IL1β activation by increasing stress hormones that induce histone hyperacetylation, allowing greater access of nuclear factor-κB to the IL1B promoter and rendering the host susceptible to aggravated immune responses. Our findings suggest that β blockers have a therapeutic potential for inflammatory bowel disease susceptibility and establish a novel paradigm whereby NI induces epigenetic susceptibility to inflammatory bowel disease.
- Published
- 2018
- Full Text
- View/download PDF
333. Differences in gut microbial composition correlate with regional brain volumes in irritable bowel syndrome.
- Author
-
Labus JS, Hollister EB, Jacobs J, Kirbach K, Oezguen N, Gupta A, Acosta J, Luna RA, Aagaard K, Versalovic J, Savidge T, Hsiao E, Tillisch K, and Mayer EA
- Subjects
- Adult, Bacteria genetics, Bacteria isolation & purification, DNA, Bacterial genetics, DNA, Ribosomal genetics, Feces microbiology, Female, Gastrointestinal Microbiome, Humans, Irritable Bowel Syndrome diagnostic imaging, Male, Phylogeny, RNA, Ribosomal, 16S genetics, Young Adult, Bacteria classification, Brain diagnostic imaging, Irritable Bowel Syndrome microbiology, Sequence Analysis, DNA methods
- Abstract
Background: Preclinical and clinical evidence supports the concept of bidirectional brain-gut microbiome interactions. We aimed to determine if subgroups of irritable bowel syndrome (IBS) subjects can be identified based on differences in gut microbial composition, and if there are correlations between gut microbial measures and structural brain signatures in IBS., Methods: Behavioral measures, stool samples, and structural brain images were collected from 29 adult IBS and 23 healthy control subjects (HCs). 16S ribosomal RNA (rRNA) gene sequencing was used to profile stool microbial communities, and various multivariate analysis approaches were used to quantitate microbial composition, abundance, and diversity. The metagenomic content of samples was inferred from 16S rRNA gene sequence data using Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt). T1-weighted brain images were acquired on a Siemens Allegra 3T scanner, and morphological measures were computed for 165 brain regions., Results: Using unweighted Unifrac distances with hierarchical clustering on microbial data, samples were clustered into two IBS subgroups within the IBS population (IBS1 (n = 13) and HC-like IBS (n = 16)) and HCs (n = 23) (AUROC = 0.96, sensitivity 0.95, specificity 0.67). A Random Forest classifier provided further support for the differentiation of IBS1 and HC groups. Microbes belonging to the genera Faecalibacterium, Blautia, and Bacteroides contributed to this subclassification. Clinical features distinguishing the groups included a history of early life trauma and duration of symptoms (greater in IBS1), but not self-reported bowel habits, anxiety, depression, or medication use. Gut microbial composition correlated with structural measures of brain regions including sensory- and salience-related regions, and with a history of early life trauma., Conclusions: The results confirm previous reports of gut microbiome-based IBS subgroups and identify for the first time brain structural alterations associated with these subgroups. They provide preliminary evidence for the involvement of specific microbes and their predicted metabolites in these correlations.
- Published
- 2017
- Full Text
- View/download PDF
334. Distinct Microbiome-Neuroimmune Signatures Correlate With Functional Abdominal Pain in Children With Autism Spectrum Disorder.
- Author
-
Luna RA, Oezguen N, Balderas M, Venkatachalam A, Runge JK, Versalovic J, Veenstra-VanderWeele J, Anderson GM, Savidge T, and Williams KC
- Abstract
Background & Aims: Emerging data on the gut microbiome in autism spectrum disorder (ASD) suggest that altered host-microbe interactions may contribute to disease symptoms. Although gut microbial communities in children with ASD are reported to differ from individuals with neurotypical development, it is not known whether these bacteria induce pathogenic neuroimmune signals., Methods: Because commensal clostridia interactions with the intestinal mucosa can regulate disease-associated cytokine and serotonergic pathways in animal models, we evaluated whether microbiome-neuroimmune profiles (from rectal biopsy specimens and blood) differed in ASD children with functional gastrointestinal disorders (ASD-FGID, n = 14) compared with neurotypical (NT) children with FGID (NT-FGID, n = 15) and without abdominal pain (NT, n = 6). Microbial 16S ribosomal DNA community signatures, cytokines, and serotonergic metabolites were quantified and correlated with gastrointestinal symptoms., Results: A significant increase in several mucosa-associated Clostridiales was observed in ASD-FGID, whereas marked decreases in Dorea and Blautia , as well as Sutterella , were evident. Stratification by abdominal pain showed multiple organisms in ASD-FGID that correlated significantly with cytokines (interleukin [IL]6, IL1, IL17A, and interferon-γ). Group comparisons showed that IL6 and tryptophan release by mucosal biopsy specimens was highest in ASD children with abdominal pain, whereas serotonergic metabolites generally were increased in children with FGIDs. Furthermore, proinflammatory cytokines correlated significantly with several Clostridiales previously reported to associate with ASD, as did tryptophan and serotonin., Conclusions: Our findings identify distinctive mucosal microbial signatures in ASD children with FGID that correlate with cytokine and tryptophan homeostasis. Future studies are needed to establish whether these disease-associated Clostridiales species confer early pathogenic signals in children with ASD and FGID.
- Published
- 2016
- Full Text
- View/download PDF
335. The Brain-Gut-Microbiome Axis: What Role Does It Play in Autism Spectrum Disorder?
- Author
-
Luna RA, Savidge TC, and Williams KC
- Abstract
The brain-gut-microbiome axis refers to the interactions between the central nervous system, gastrointestinal system, and microorganisms that live in the gastrointestinal tract. Exploring these interactions provides a rationale for why gastrointestinal disorders commonly occur in children with Autism Spectrum Disorders (ASD). Signs of altered brain-gut interactions that are closely associated with functional GI disorders (FGIDs) commonly occur in children with ASD. Studies of microbiome in ASD suggest that changes in the gut microbiome may be associated with ASD and with GI disorders in children with ASD. Further studies into the brain-gut-microbiome axis could lead to new techniques for identifying GI disorders in children with ASD and novel therapies for treating ASD behaviors.
- Published
- 2016
- Full Text
- View/download PDF
336. Glial Orchestrated Neurodegeneration: An Important Crossroad for Neural Stem Cell Therapy to the Intestine.
- Author
-
Savidge TC
- Published
- 2015
- Full Text
- View/download PDF
337. BIOPHYSICS. Comment on "Extreme electric fields power catalysis in the active site of ketosteroid isomerase".
- Author
-
Chen D and Savidge T
- Subjects
- Ketosteroids metabolism, Static Electricity, Steroid Isomerases chemistry
- Abstract
Fried et al. (Reports, 19 December 2014, p. 1510) demonstrate electric field-dependent acceleration of biological catalysis using ketosteroid isomerase as a prototypic example. These findings were not extended to aqueous solution because water by itself has field fluctuations that are too large and fast to provide a catalytic effect. Given physiological context, when water electrostatic interactions are considered, electric fields play a less important role in the catalysis., (Copyright © 2015, American Association for the Advancement of Science.)
- Published
- 2015
- Full Text
- View/download PDF
338. Importance of NO and its related compounds in enteric nervous system regulation of gut homeostasis and disease susceptibility.
- Author
-
Savidge TC
- Subjects
- Animals, Disease Susceptibility, Gastrointestinal Tract innervation, Homeostasis, Humans, Enteric Nervous System metabolism, Gastrointestinal Tract metabolism, Nitric Oxide metabolism
- Abstract
Nitric oxide (NO) produced by the enteric nervous system represents an important regulatory mechanism in gut homeostasis. Aberrant NO signaling contributes significantly toward enteric disease by altering gut motility, vascular tone, blood supply, mucosal barrier function, secretions and immunity. Consequently, there is much interest in therapeutically targeting NO production and its bioactive intermediates. This article highlights recent advances in NO signaling and therapeutics as it relates to the gastrointestinal tract and its associated NO producing microbiota. Because of its limited scope, a particular emphasis is placed on S-nitrosylation as the emerging physiologic mechanism for NO signal transduction, and how such signals are modulated by other gaseous transmitters - notably hydrogen disulfide and carbon monoxide - that are produced by the enteric nervous system and share common molecular targets. Recent findings also indicate that druggable regulators of S-nitrosylation, for example S-nitrosoglutathione (GSNO) reductase, provide for a superior pharmacology and finer therapeutic control over classical NO donors, and may be better suited for oral delivery to the gastrointestinal tract., (Copyright © 2014 Elsevier Ltd. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
339. Clostridial toxins: sensing a target in a hostile gut environment.
- Author
-
Oezguen N, Power TD, Urvil P, Feng H, Pothoulakis C, Stamler JS, Braun W, and Savidge TC
- Subjects
- Anti-Bacterial Agents therapeutic use, Clostridium Infections drug therapy, Clostridium Infections epidemiology, Clostridium Infections microbiology, Colitis drug therapy, Colitis epidemiology, Colitis microbiology, Diarrhea drug therapy, Diarrhea epidemiology, Diarrhea microbiology, Humans, Metronidazole therapeutic use, Vancomycin therapeutic use, Virulence Factors antagonists & inhibitors, Virulence Factors metabolism, Antitoxins therapeutic use, Bacterial Proteins antagonists & inhibitors, Bacterial Proteins metabolism, Bacterial Toxins antagonists & inhibitors, Clostridioides difficile pathogenicity, Enterotoxins antagonists & inhibitors, Enterotoxins metabolism, Gastrointestinal Tract microbiology
- Abstract
The current global outbreak of Clostridium difficile infection exemplifies the major public health threat posed by clostridial glucosylating toxins. In the western world, C. difficile infection is one of the most prolific causes of bacterial-induced diarrhea and potentially fatal colitis. Two pathogenic enterotoxins, TcdA and TcdB, cause the disease. Vancomycin and metronidazole remain readily available treatment options for C. difficile infection, but neither is fully effective as is evident by high clinical relapse and fatality rates. Thus, there is an urgent need to find an alternative therapy that preferentially targets the toxins and not the drug-resistant pathogen. Recently, we addressed these critical issues in a Nature Medicine letter, describing a novel host defense mechanism for subverting toxin virulence that we translated into prototypic allosteric therapy for C. difficile infection. In this addendum article, we provide a continued perspective of this antitoxin mechanism and consider the broader implications of therapeutic allostery in combating gut microbial pathogenesis.
- Published
- 2012
- Full Text
- View/download PDF
340. Enteric glia protect against Shigella flexneri invasion in intestinal epithelial cells: a role for S-nitrosoglutathione.
- Author
-
Flamant M, Aubert P, Rolli-Derkinderen M, Bourreille A, Neunlist MR, Mahé MM, Meurette G, Marteyn B, Savidge T, Galmiche JP, Sansonetti PJ, and Neunlist M
- Subjects
- Animals, Anti-Bacterial Agents pharmacology, Bacterial Translocation physiology, Caco-2 Cells, Coculture Techniques, Colon innervation, Colon microbiology, Drug Evaluation, Preclinical methods, Dysentery, Bacillary microbiology, Dysentery, Bacillary physiopathology, Enteric Nervous System physiology, Humans, Intestinal Mucosa drug effects, Intestinal Mucosa metabolism, Permeability, Rabbits, Reverse Transcriptase Polymerase Chain Reaction, S-Nitrosoglutathione pharmacology, Shigella flexneri drug effects, cdc42 GTP-Binding Protein metabolism, Dysentery, Bacillary pathology, Intestinal Mucosa innervation, Neuroglia physiology, S-Nitrosoglutathione metabolism, Shigella flexneri physiology
- Abstract
Background: Enteric glial cells (EGCs) are important regulators of intestinal epithelial barrier (IEB) functions. EGC-derived S-nitrosoglutathione (GSNO) has been shown to regulate IEB permeability. Whether EGCs and GSNO protect the IEB during infectious insult by pathogens such as Shigella flexneri is not known., Methods: S flexneri effects were characterised using in vitro coculture models of Caco-2 cells and EGCs (or GSNO), ex vivo human colonic mucosa, and in vivo ligated rabbit intestinal loops. The effect of EGCs on S flexneri-induced changes in the invasion area and the inflammatory response were analysed by combining immunohistochemical, ELISA and PCR methods. Expression of small G-proteins was analysed by western blot. Expression of ZO-1 and localisation of bacteria were analysed by fluorescence microscopy., Results: EGCs significantly reduced barrier lesions and inflammatory response induced by S flexneri in Caco-2 monolayers. The EGC-mediated effects were reproduced by GSNO, but not by reduced glutathione, and pharmacological inhibition of pathways involved in GSNO synthesis reduced EGC protecting effects. Furthermore, expression of Cdc42 and phospho-PAK in Caco-2 monolayers was significantly reduced in the presence of EGCs or GSNO. In addition, changes in ZO-1 expression and distribution induced by S flexneri were prevented by EGCs and GSNO. Finally, GSNO reduced S flexneri-induced lesions of the IEB in human mucosal colonic explants and in a rabbit model of shigellosis., Conclusion: These results highlight a major protective function of EGCs and GSNO in the IEB against S flexneri attack. Consequently, this study lays the scientific basis for using GSNO to reduce barrier susceptibility to infectious or inflammatory challenge.
- Published
- 2011
- Full Text
- View/download PDF
341. Urocortin II mediates pro-inflammatory effects in human colonocytes via corticotropin-releasing hormone receptor 2alpha.
- Author
-
Moss AC, Anton P, Savidge T, Newman P, Cheifetz AS, Gay J, Paraschos S, Winter MW, Moyer MP, Karalis K, Kokkotou E, and Pothoulakis C
- Subjects
- Animals, Bacterial Toxins immunology, Cell Line, Colitis immunology, Colitis, Ulcerative immunology, Colon cytology, Crohn Disease immunology, Enterotoxins immunology, Gene Expression Regulation immunology, Humans, Interleukin-8 immunology, Intestines transplantation, Mice, Mice, SCID, Mitogen-Activated Protein Kinases immunology, NF-kappa B immunology, RNA, Messenger analysis, Transplantation, Heterologous, Tumor Necrosis Factor-alpha immunology, Urocortins, Colon immunology, Corticotropin-Releasing Hormone immunology, Epithelial Cells immunology, Receptors, Corticotropin-Releasing Hormone immunology
- Abstract
Background/aims: Urocortin II (UcnII) is a neuropeptide that binds with high affinity to the corticotropin-releasing hormone receptor 2 (CRHR2) in peripheral tissues. UcnII is synthesised in the intestine, but its role in human intestinal inflammation is largely unknown., Methods: Responses of human colonic epithelial cells expressing CRHR2 to stimulation by UcnII were measured using ELISA, western blot analysis, real-time reverse transcription-PCR (RT-PCR) and interleukin (IL)8 promoter activity. Expression levels of CRHR2 and UcnII in human colitis were determined by immunofluorescence and real-time RT-PCR in mucosal biopsies from patients with Crohn's and ulcerative colitis, and in human intestinal xenografts after exposure to Clostridium difficile toxin A., Results: It is reported here that expression of CRHR2 mRNA and protein in human colonic epithelial cells (HT-29) are increased by exposure to C difficile toxin A or tumour necrosis factor (TNF)alpha. Stimulation of non-transformed NCM460 colonocytes overexpressing CRHR2alpha receptor with UcnII resulted in a time- and concentration-dependent increase in IL8 production. UcnII stimulation also led to activation of nuclear factor-kappaB (NF-kappaB) and mitogen-acivated protein (MAP) kinase in these cells, as evidenced by degradation of IkappaBalpha and phosphorylation of the p65 subunit of NF-kappaB and extracellularly regulated kinase (ERK) 1/2. Furthermore, expression of UcnII and CRHR2 mRNA was increased in mucosal samples of patients with inflammatory bowel disease, and after exposure of human intestinal xenografts to C difficile toxin A., Conclusions: These results suggest that UcnII has pro-inflammatory effects in human intestinal cells via the CRHR2alpha receptor and may play an important role in the pathophysiology of colitis in humans.
- Published
- 2007
- Full Text
- View/download PDF
342. Starring roles for astroglia in barrier pathologies of gut and brain.
- Author
-
Savidge TC, Sofroniew MV, and Neunlist M
- Subjects
- Animals, Astrocytes physiology, Blood-Brain Barrier physiopathology, Enteric Nervous System physiopathology, Humans, Intestinal Mucosa innervation, Peripheral Nervous System Diseases pathology, Peripheral Nervous System Diseases physiopathology, Astrocytes pathology, Blood-Brain Barrier pathology, Brain pathology, Enteric Nervous System pathology, Gastrointestinal Diseases pathology, Intestinal Mucosa pathology
- Abstract
The gastrointestinal tract is a highly innervated organ and enteric neuropathy is emerging as a central feature of a wide range of gut diseases. Although most considerations of the enteric nervous system have focused on neuronal dysfunction, a large population of astrocyte-like glia populates gut muscle layers and the intestinal mucosa, and mounting new evidence points toward enteric glia as active participants in gut pathology. Similarly, in the central nervous system increasing evidence suggests that dysfunctions of astrocytes play central roles in disease mechanisms. On the basis of the premise that gut-brain disease paradigms may exist, we explore the possibility that enteric glia constitute a previously unrecognized disease target in pathologies associated with intestinal barrier dysfunction, notably inflammatory bowel disease, necrotizing enterocolitis, irritable bowel syndrome, diabetes, autoimmune disease and neurotrophic virus infection of the gut.
- Published
- 2007
- Full Text
- View/download PDF
343. Identification of hepoxilin A3 in inflammatory events: a required role in neutrophil migration across intestinal epithelia.
- Author
-
Mrsny RJ, Gewirtz AT, Siccardi D, Savidge T, Hurley BP, Madara JL, and McCormick BA
- Subjects
- Humans, Salmonella typhimurium physiology, 8,11,14-Eicosatrienoic Acid analogs & derivatives, 8,11,14-Eicosatrienoic Acid metabolism, Inflammation pathology, Intestinal Mucosa cytology, Neutrophils cytology
- Abstract
The mechanism by which neutrophils [polymorphonuclear leukocyte (PMNs)] are stimulated to move across epithelial barriers at mucosal surfaces has been basically unknown in biology. IL-8 has been shown to stimulate PMNs to leave the bloodstream at a local site of mucosal inflammation, but the chemical gradient used by PMNs to move between adjacent epithelial cells and traverse the tight junction at the apical neck of these mucosal barriers has eluded identification. Our studies not only identify this factor, previously termed pathogen-elicited epithelial chemoattractant, as the eicosanoid hepoxilin A(3) (hepA(3)) but also demonstrate that it is a key factor promoting the final step in PMN recruitment to sites of mucosal inflammation. We show that hepA(3) is synthesized by epithelial cells and secreted from their apical surface in response to conditions that stimulate inflammatory events. Our data further establish that hepA(3) acts to draw PMNs, via the establishment of a gradient across the epithelial tight junction complex. The functional significance of hepA(3) to target PMNs to the lumen of the gut at sites of inflammation was demonstrated by the finding that disruption of the 12-lipoxygenase pathway (required for hepA(3) production) could dramatically reduce PMN-mediated tissue trauma, demonstrating that hepA(3) is a key regulator of mucosal inflammation.
- Published
- 2004
- Full Text
- View/download PDF
344. Region-specific ontogeny of alpha-2,6-sialyltransferase during normal and cortisone-induced maturation in mouse intestine.
- Author
-
Dai D, Nanthakumar NN, Savidge TC, Newburg DS, and Walker WA
- Subjects
- Animals, Animals, Suckling, Asialoglycoproteins metabolism, Carbohydrate Conformation, Colon enzymology, Duodenum enzymology, Fetuins, Fluorescein-5-isothiocyanate, Fluorescent Dyes, Glycoconjugates analysis, Ileum enzymology, Intestines drug effects, Jejunum enzymology, Lectins, Mice, N-Acetylneuraminic Acid metabolism, RNA, Messenger analysis, Ribosome Inactivating Proteins, Sialyltransferases genetics, Tissue Distribution, alpha-Fetoproteins metabolism, Aging, Cortisone pharmacology, Intestines enzymology, Intestines growth & development, Plant Lectins, Sialyltransferases metabolism
- Abstract
Regional differences in the ontogeny of mouse intestinal alpha-2,6-sialyltransferase activities (alpha-2,6-ST) and the influence of cortisone acetate (CA) on this expression were determined. High ST activity and alpha-2,6-ST mRNA levels were detected in immature small and large intestine, with activity increasing distally from the duodenum. As the mice matured, ST activity (predominantly alpha-2,6-ST) in the small intestine decreased rapidly to adult levels by the fourth postnatal week. CA precociously accelerated this region-specific ontogenic decline. A similar decline of ST mRNA levels reflected ST activity in the small, but not the large, intestine. Small intestinal sialyl alpha-2,6-linked glycoconjugates displayed similar developmental and CA induced-precocious declines when probed using Sambucus nigra agglutinin (SNA) lectin. SNA labeling demonstrated age-dependent diminished sialyl alpha2,6 glycoconjugate expression in goblet cells in the small (but not large) intestine, but no such regional specificity was apparent in microvillus membrane. This suggests differential regulation of sialyl alpha-2,6 glycoconjugates in absorptive vs. globlet cells. These age-dependent and region-specific differences in sialyl alpha-2,6 glycoconjugates may be mediated in part by altered alpha-2,6-ST gene expression regulated by trophic factors such as glucocorticoids.
- Published
- 2002
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.